Robert Zirkelbach

Today, we're launching America Cures, a new campaign that highlights the need to keep our American leadership in medicine development. For decades, America has led the world in medicine and the benefits are clear: Americans get access to new medicines nearly 3 years earlier than people in other wealthy countries. The biopharmaceutical industry supports more than 5 million jobs. Not relying on other countries for medical innovation protects U.S. national security. But now, our innovation ecosystem is at risk. China is poised to become the next biopharmaceutical powerhouse. American leadership matters. We will need to work together as an industry to define the next era of American leadership and enable the next generation of American cures. americacures.com

New data show some tax-exempt hospitals mark up medicines by more than 10,000%, with no requirement that patients benefit. That’s not patient assistance, it’s a buy low, sell high business strategy. Read more in our new blog: phrma.org/blog/340b-hosp…

There is a reason we don't price medicines like other countries - becuse they set prices in a way that systematically discriminate against seniors, people with disabilities and those with chronic illnesses.

U.S. leadership in biopharma didn’t happen overnight. Our success was built over decades of investment, strong IP protections and pro-innovation policies. To keep the next generation of breakthroughs here, we must protect that foundation. Click through our timeline to learn the history: #smart-policy" target="_blank" rel="nofollow noopener">innovation.org/breakthroughs/…

Approval of a medicine is the beginning, not the end. Hear from Pamela Gavin of @RareDiseases during our PhRMA Forum about how we must tackle the coverage denials and insurance hurdles that block patient access.

The race for the future of medicine is on and the U.S. is losing ground. China now holds 39% of cell and gene therapy trial sites. That is double the U.S. share. We must protect American innovation to ensure our patients are the first to benefit rather than the last. Learn more: phrma.org/blog/new-repor…

Big tax-exempt hospitals generated $1.8B in #340B program profits from overcharging patients enrolled in state employee health plans according to new data from @IQVIA_global. It’s time to fix 340B. phrma.org/blog/340b-hosp…

For decades, America has led the world in medicine development. Two thirds of medicines consumed in the U.S. are made in America. That strengthens supply chains and national security. We must protect the policies that keep innovation and manufacturing here at home.

The future of health care is already here — and it’s powered by AI. At PhRMA Forum @jackdent, @BenjamineYLiu and I discussed how AI will allow medical discoveries to be made more precisely and efficiently, ultimately advancing how we can deliver new treatments to patients. This isn’t some futuristic endeavor – this is happening now. Watch the full conversation here: youtu.be/bhZ3LB1dx6I?t=2

Really enjoyed moderating this conversation. Fascinating perspectives from @jackdent and @BenjamineYLiu.

New reporting from The New York Times shows how the 340B program’s lack of transparency and guardrails has allowed it to function as a hospital markup program, driving up costs for patients, taxpayers and employers. As scrutiny grows from Congress and others, it’s clear that patients aren’t benefitting. It’s time to fix 340B. nytimes.com/2026/02/12/us/…

AI has the power to transform the way we develop new treatments and cures. This means our industry’s R&D can become more efficient, getting cutting edge medicines to patients faster. I am personally looking forward to seeing how our companies’ researchers leverage this new technology.

Thank you to everyone who joined us at PhRMA Forum today. We discussed critical issues shaping the future of the biopharmaceutical industry, including AI innovation in medicine, continued progress in rare disease research and important conversations with CMS Administrator @DrOzCMS and FDA Commissioner Dr. @DrMakaryFDA on American leadership. A key takeaway: sustaining American leadership in biopharma will require continued focus and commitment. innovation.org/phrma-forum/

Today at PhRMA Forum, I had the privilege of discussing the power of AI in health care with @jackdent and @BenjamineYLiu. AI has the potential to transform drug discovery and development. Even just looking at the start of 2025 to today, the results of this new technology are unimaginable. AI is helping scientists design better medicines, eliminate bad ideas earlier and run faster clinical trials. This is why it’s essential for America to continue leading in technology and biopharma innovation. We must do all we can to accelerate the next generation of treatments and cures.

The biopharma industry is stepping up. Today, we launch America’s Medicines, a new tool that gives patients more options to afford and get their medicines. Middlemen excluded 1,453 medicines this year and drive up costs for 80M+ Americans. Affordability for all requires fixing

Big news from Boston: Takeda is investing $30 billion in U.S. manufacturing and R&D through the end of the decade. Takeda’s presence in the area has helped make it a global innovation hub, and this investment ensures that it will remain so for years to come:

Yesterday, I testified at the Energy & Commerce hearing. My thoughts on the experience here: linkedin.com/posts/lorireil…

Congratulations to @NovartisUS on their Radioligand Therapy facility in Carlsbad, California. Part of their $23 billion investment in the U.S. announced in 2025, the lab reflects Novartis’s commitment to American innovation and is a testament to the power of smart policies.